Yahoo
    NasdaqGM - Nasdaq Real Time Price USD

    Bicara Therapeutics Inc. (BCAX)

    9.13 -0.60 (-6.17%)
    At close: October 30 at 4:00:01 PM EDT
    8.98 -0.15 (-1.65%)
    After hours: October 30 at 7:42:33 PM EDT
    Trade BCAX on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for BCAX
    • Previous Close 9.73
    • Open 9.38
    • Bid 18.74 x 200
    • Ask 32.75 x 200
    • Day's Range 8.36 - 9.38
    • 52 Week Range 8.36 - 30.99
    • Volume 4,195,035
    • Avg. Volume 973,120
    • Market Cap (intraday) 604.159M
    • Beta (5Y Monthly) -0.69
    • PE Ratio (TTM) --
    • EPS (TTM) -3.08
    • Earnings Date Nov 10, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 34.92
    • Motley Fool Rating Bullish

    Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

    www.bicara.com

    103

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Bicara Therapeutics Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    BCAX
    45.75%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    BCAX
    44.53%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    BCAX
    65.22%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    BCAX
    65.22%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -55.44M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -50M
    -40M
    -30M
    -20M
    -10M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    20.00
    34.92 Average
    9.13 Current
    45.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/30/2026
    Analyst Goldman Sachs
    Rating Action Downgrade
    Rating Sell
    Price Action Lowers
    Price Target 20 -> 8
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -26.14%

    • Return on Equity (ttm)

      -41.01%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -185.36M

    • Diluted EPS (ttm)

      -3.08

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      497.26M

    • Total Debt/Equity (mrq)

      0.25%

    • Levered Free Cash Flow (ttm)

      -76.95M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    MBX MBX Biosciences, Inc.
    55.87 +2.44%
    AVBP ArriVent BioPharma, Inc.
    14.87 -6.77%
    UPB Upstream Bio, Inc.
    3.4100 +4.28%
    RAPP Rapport Therapeutics, Inc.
    25.05 +3.47%
    ZBIO Zenas BioPharma, Inc.
    28.39 -1.29%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: